Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DFTX Definium Therapeutics

Pre-Mkt 06-30 09:21:16 EDT

46.55

+1.60

+3.56%

盘前46.40

-0.15-0.32%

09:15 EDT

High47.20	Low44.25	Vol4.67M
Open44.26	D1 Closing44.95	Amplitude6.56%
Mkt Cap6.05B	Tradable Cap6.00B	Total Shares130.00M
T/O214.48M	T/O Rate3.62%	Tradable Shares129.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":46.55,"timestamp":1782763200000,"preClose":44.95,"halted":0,"volume":4674746,"hourTrading":{"tag":"盘前","latestPrice":46.4,"preClose":46.55,"latestTime":"09:15 EDT","volume":7013,"amount":325909.25808,"timestamp":1782825315561,"change":-0.15,"changeRate":-0.003222,"amplitude":0.020213},"delay":0,"changeRate":0.035595105672969835,"floatShares":129000000,"shares":130000000,"eps":-2.49367,"marketStatus":"Pre-Mkt","change":1.6,"latestTime":"06-30 09:21:16 EDT","open":44.26,"high":47.2,"low":44.25,"amount":214477369.85373,"amplitude":0.065628,"askPrice":46.6,"askSize":1,"bidPrice":46.24,"bidSize":45,"shortable":3,"etf":0,"ttmEps":-2.49367,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782826200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":46.55,"preHourTrading":{"tag":"盘前","latestPrice":46.4,"preClose":46.55,"latestTime":"09:15 EDT","volume":7013,"amount":325909.25808,"timestamp":1782825315561,"change":-0.15,"changeRate":-0.003222,"amplitude":0.020213},"postHourTrading":{"tag":"盘后","latestPrice":46.5215,"preClose":46.55,"latestTime":"19:57 EDT","volume":39445,"amount":1836157.2365,"timestamp":1782777454406,"change":-0.0285,"changeRate":-0.000612,"amplitude":0.008206},"volumeRatio":0.3978580805831636,"impliedVol":0.89,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/DFTX/wiki","defaultTab":"wiki","newsList":[{"id":"2646397771","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2646397771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646397771?lang=en_us&edition=fundamental","pubTime":"2026-06-27 22:30","pubTimestamp":1782570614,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definium Therapeutics (DFTX) and Eledon Pharmaceutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-236?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-236?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646385769","title":"Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2646385769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646385769?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:24","pubTimestamp":1782419085,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nFWN42X0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646129385","title":"Definium Therapeutics Closes USD 805 Million Upsized Follow-on Offering at USD 34 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2646129385","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646129385?lang=en_us&edition=fundamental","pubTime":"2026-06-26 04:15","pubTimestamp":1782418541,"startTime":"0","endTime":"0","summary":"Definium Therapeutics closes USD 805 million upsized follow-on offering at USD 34 per shareDefinium Therapeutics closed an upsized underwritten public offering of 23,676,471 common shares at USD 34 pe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDLcfdgfY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100061988","title":"Movement Alert｜Definium Therapeutics Rises 9.07% in Regular Trading, Phase 3 EMERGE Study Hits Primary Endpoint and $700 Million Offering Priced","url":"https://stock-news.laohu8.com/highlight/detail?id=1100061988","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100061988?lang=en_us&edition=fundamental","pubTime":"2026-06-25 22:26","pubTimestamp":1782397592,"startTime":"0","endTime":"0","summary":"On June 25, Definium Therapeutics rose 9.07% in regular trading, trading at $45.455/share, with turnover of approximately $98.63 million. The stock continued its momentum driven by multiple positive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646284904","title":"Definium Therapeutics Announces Major Public Equity Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2646284904","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646284904?lang=en_us&edition=fundamental","pubTime":"2026-06-25 05:27","pubTimestamp":1782336451,"startTime":"0","endTime":"0","summary":"The latest update is out from Definium Therapeutics ( ($DFTX) ). On June 23, 2026, Definium Therapeutics, Inc. entered into an underwriting agreeme...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-announces-major-public-equity-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/definium-therapeutics-announces-major-public-equity-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4585","EQR","BK4007","DFTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646281070","title":"Definium Therapeutics is Maintained at Buy by Jones Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2646281070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646281070?lang=en_us&edition=fundamental","pubTime":"2026-06-25 02:29","pubTimestamp":1782325740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/DFTX/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 14:29 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819648","title":"Definium Therapeutics rises 17.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645819648?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:05","pubTimestamp":1782309951,"startTime":"0","endTime":"0","summary":"Definium Therapeutics (DFTX) is up 17.7%, or $6.40 to $42.58. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-rises-17-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-rises-17-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166167066","title":"Movement Alert｜Definium Therapeutics Rises 15.48% in Regular Trading, Trading at $42.495","url":"https://stock-news.laohu8.com/highlight/detail?id=1166167066","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166167066?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:01","pubTimestamp":1782309693,"startTime":"0","endTime":"0","summary":"On June 24, Definium Therapeutics rose 15.48% in regular trading, trading at $42.495/share, with Turnover of $157 million.Within the Pharmacy sector where Definium Therapeutics belongs, the overall...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645581611","title":"Definium Therapeutics Soars Again After Upsized $700 Mln Equity Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2645581611","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645581611?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:56","pubTimestamp":1782309374,"startTime":"0","endTime":"0","summary":"BUZZ-Definium Therapeutics soars again after upsized $700 mln equity raise** Definium Therapeutics;DFTX.Oshares up 16.1% to $42 in early Weds trading after above-target $700 mln haul** DFTX late Tues announced pricing ~20.6 mln share offering at $34** On Mon, DFTX's stock soared 50% to $36.67 after co said its LSD-based drug, DT120,significantly reduced symptomsof major depression in patients in late-stage trial** After the bell Mon, counveiled$500 mln offering for R&D of its product candidates, preparation activities for potential commercialization of DT120, among other purposes** JP Morgan, Jefferies, Leerink and BofA joint lead bookrunners** Stock has more than tripled YTD** All 16 analysts covering the stock are bullish including 6 \"strong buy\" ratings; median PT $52, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL6N42W0VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU2023250330.USD","IE00BN8TJ469.HKD","LU0211327993.USD","LU0203345920.USD","LU1551013425.SGD","IE000M9KFDE8.USD","JPMO","LU1119994496.HKD","LU1280957306.USD","LU2417539215.USD","BK0090","BK0010","IE00BLSP4452.SGD","JPX","600776","LU0234572021.USD","LU2756315664.SGD","LU1917777945.USD","JPO","LU2054465674.USD","LU0320765646.SGD","LU0976567544.SGD","DFTX","LU2237443549.SGD","LU2505996681.GBP","BK4007","LU1032466523.USD","BK4516","LU2237443978.SGD","IE00BJLML261.HKD","BK4550","LU0868494708.USD","LU0820562030.AUD","LU1974910355.USD","LU1670628061.USD","LU0859254822.USD","LU2462157665.USD","LU0345770308.USD","LU0208291251.USD","LU0265550359.USD","LU1496350502.SGD","LU0106261372.USD","LU2357305700.SGD","LU2505996509.AUD","LU0256863902.USD","LU2746668974.SGD","IE00BZ1G4Q59.USD","LU0070302665.USD","LU0787776722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645894309","title":"Definium Therapeutics 20.6M share Secondary priced at $34.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2645894309","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645894309?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:20","pubTimestamp":1782296419,"startTime":"0","endTime":"0","summary":"The deal size was increased to $700M in common stock from $500M in common stock. JPMorgan, Jefferies, Leerink and BofA acted as joint book running ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-20-6m-share-secondary-priced-at-34-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-20-6m-share-secondary-priced-at-34-00-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0106831901.USD","IE0034235188.USD","LU0640476718.USD","LU0859254822.USD","LU2552382215.SGD","LU0070302665.USD","LU0267386448.USD","PGF","JPMO","LU1280957306.USD","LU2242649171.HKD","IE00BWXC8680.SGD","LU0265550359.USD","LU0149725797.USD","LU2357305700.SGD","IE00BLSP4452.SGD","DFTX","LU1244550494.USD","LU2746668974.SGD","JPX","LU1974910355.USD","LU2213496289.HKD","BK4504","IE00B1XK9C88.USD","LU1496350502.SGD","LU1244550221.USD","LU0323591593.USD","LU0265550946.USD","BK4533","LU1116320901.HKD","LU2505996509.AUD","LU0320765646.SGD","SG9999002232.USD","LU2592432038.USD","LU1551013342.USD","BK4534","IE0034235303.USD","LU1032466523.USD","LU0964807845.USD","LU0203345920.USD","LU0882574139.USD","SG9999002224.SGD","LU0170899867.USD","LU2505996681.GBP","LU2106854487.HKD","LU2244417387.USD","JPO","LU0689472784.USD","LU1894683264.USD","LU0211327993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645955468","title":"Definium Therapeutics price target raised to $74 from $61 at JonesResearch","url":"https://stock-news.laohu8.com/highlight/detail?id=2645955468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645955468?lang=en_us&edition=fundamental","pubTime":"2026-06-24 16:40","pubTimestamp":1782290413,"startTime":"0","endTime":"0","summary":"JonesResearch raised the firm’s price target on Definium Therapeutics (DFTX) to $74 from $61 and keeps a Buy rating on the shares after the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-74-from-61-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-74-from-61-at-jonesresearch-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645863005","title":"BRIEF-Definium Prices Offering Of 20.59 Million Shares At $34/Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2645863005","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645863005?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:58","pubTimestamp":1782266332,"startTime":"0","endTime":"0","summary":"BRIEF-Definium Prices Offering Of 20.59 Million Shares At $34/ShareJune 23 (Reuters) - Definium Therapeutics Inc DFTX.O:DEFINIUM THERAPEUTICS, INC. ANNOUNCES PRICING OF $700 MILLION UPSIZED PUBLIC OFF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUABTBPTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645006863","title":"Definium Therapeutics prices upsized public offering at USD 700 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645006863","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645006863?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:57","pubTimestamp":1782266235,"startTime":"0","endTime":"0","summary":"Definium Therapeutics priced an upsized underwritten follow-on offering of 20,588,236 common shares at USD 34 per share.Gross proceeds expected to total about USD 700 million, before underwriting discounts, commissions, and offering expenses.Underwriters hold a 30-day option to buy up to 3,088,235 additional common shares at the offering price, less discounts and commissions.Net proceeds earmarked for R&D, pre-commercialization work for DT120 ODT if approved, working capital, and general corporate purposes.Closing targeted for about June 25, 2026, subject to customary conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire  o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDLbsVN9d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645863076","title":"Definium Therapeutics - Prices Public Offering of 20.59 Mln Shares at $34 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2645863076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645863076?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:57","pubTimestamp":1782266220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUABTBPTK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645079863","title":"Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645079863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645079863?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:57","pubTimestamp":1782266220,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUABTBPTK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645241838","title":"Definium Therapeutics price target raised to $57 from $37 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2645241838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645241838?lang=en_us&edition=fundamental","pubTime":"2026-06-23 18:50","pubTimestamp":1782211811,"startTime":"0","endTime":"0","summary":"Baird analyst Christopher Chen raised the firm’s price target on Definium Therapeutics (DFTX) to $57 from $37 and keeps an Outperform rating on the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-37-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/definium-therapeutics-price-target-raised-to-57-from-37-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645852618","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys","url":"https://stock-news.laohu8.com/highlight/detail?id=2645852618","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645852618?lang=en_us&edition=fundamental","pubTime":"2026-06-23 15:27","pubTimestamp":1782199671,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, GE Healthcare, Synopsys June 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nL8N42V0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV","APH","DPZ","AVXX","E","BE","BEG","KMX","ANET","CDW","AAL","ACLS","BPH","CNCG","BEZ","LABX","D","CELH","BNY","CPB","ALGT","ALLY","APGE","BEX","GEHC","ASH","BP","DFTX","DLLL","AEIS","BAC","DXCM","AMAT","CHPT","CAR","ALK","DAR","BBWI","CELT","CNC","ARES","ACN","BTI","AHR","ALAB","DAL","AVAV","DELL","CTSH","CAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645002748","title":"Definium Therapeutics Inc : Canaccord Genuity Raises Target Price to $60 From $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2645002748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645002748?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:49","pubTimestamp":1782186572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42U04Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645032910","title":"Under the Radar: Definium Shares Propelled by Strong Psychedelic Results -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2645032910","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645032910?lang=en_us&edition=fundamental","pubTime":"2026-06-23 06:40","pubTimestamp":1782168000,"startTime":"0","endTime":"0","summary":"Shares of Definium Therapeutics surged 50% on Monday after the biotech announced that a single dose of its LSD drug significantly eased symptoms of depression in a late-stage trial.The drug, called DT120, beat a placebo by 8.1 points on a 60-point depression scale doctors use to track symptoms, six weeks after a single dose. The benefit held at the three-month mark.DT120 is a pharmaceutically formulated version of LSD that dissolves on the tongue. It is part of a wave of psychedelic drugs-which also include psilocybin and MDMA-that researchers are testing to treat mental-health conditions. President Trump signed an executive order aimed at speeding up research and development for psychedelic drugs in April.Stifel analysts said the results \"exceeded expectations with clear and highly robust efficacy\" in a research note.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645303070","title":"Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD","url":"https://stock-news.laohu8.com/highlight/detail?id=2645303070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645303070?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:31","pubTimestamp":1782160272,"startTime":"0","endTime":"0","summary":"Definium highlighted DT120 ODT, a single-dose lysergide therapy, as its lead late-stage program in five Phase 3 studies for GAD, MDD.Emerge Phase 3 topline data in MDD met the primary endpoint; 8.1-point MADRS improvement over placebo at week 6 .Durability signal extended to week 12; 7.3-point MADRS improvement over placebo ; CGI-S improved by 0.9 at day 2 .Safety update showed no serious adverse events in Emerge through week 12; 99% of AEs were mild-to-moderate; no suicidality signal.Balance sheet showed cash, cash equivalents, investments of USD 373.4 million as of March 31, 2026; runway expected into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6zMSc2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.definiumtx.com;ir.definiumtx.com","stockEarnings":[{"period":"1week","weight":0.2694},{"period":"1month","weight":0.9243},{"period":"3month","weight":1.463},{"period":"6month","weight":2.4765},{"period":"1year","weight":6.1069},{"period":"ytd","weight":2.4765}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.1394},{"period":"6month","weight":0.0866},{"period":"1year","weight":0.2051},{"period":"ytd","weight":0.0866}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.130491},{"month":2,"riseRate":0.8,"avgChangeRate":0.136845},{"month":3,"riseRate":0.4,"avgChangeRate":0.072082},{"month":4,"riseRate":0.8,"avgChangeRate":0.037703},{"month":5,"riseRate":0.5,"avgChangeRate":0.01554},{"month":6,"riseRate":0.5,"avgChangeRate":0.061386},{"month":7,"riseRate":0.8,"avgChangeRate":0.20763},{"month":8,"riseRate":0.2,"avgChangeRate":-0.091548},{"month":9,"riseRate":0.2,"avgChangeRate":-0.174855},{"month":10,"riseRate":0.6,"avgChangeRate":0.009639},{"month":11,"riseRate":0.4,"avgChangeRate":0.026551},{"month":12,"riseRate":0.4,"avgChangeRate":-0.08416}],"exchange":"NASDAQ","name":"Definium Therapeutics","nameEN":"Definium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Definium Therapeutics,DFTX,Definium Therapeutics股票,Definium Therapeutics股票老虎,Definium Therapeutics股票老虎国际,Definium Therapeutics行情,Definium Therapeutics股票行情,Definium Therapeutics股价,Definium Therapeutics股市,Definium Therapeutics股票价格,Definium Therapeutics股票交易,Definium Therapeutics股票购买,Definium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Definium Therapeutics(DFTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Definium Therapeutics(DFTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}